Bay Street News, 2024

GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected […]

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for January 2024 on its […]

GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing […]

MINNEAPOLIS, Feb. 05, 2024 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing […]

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing […]

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) — Rigetti UK Limited, a wholly owned subsidiary of Rigetti Computing, Inc. (Nasdaq: RGTI) […]

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate […]

TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX:ILLM) (“illumin” or the “Company”) announced that effective today, Mr. […]

TAMPA, Fla., Feb. 05, 2024 (GLOBE NEWSWIRE) — Kforce Inc. (Nasdaq: KFRC), a solutions firm that specializes in technology and […]

WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect […]